Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations - 16/08/20
Background |
Little is known about the impact of accountable care organizations (ACO) on hospitalized heart failure (HF) patients, a high-cost and high-risk population.
Objective |
We linked Medicare fee-for-service claims from 2013 to 2015 with data from American Heart Association Get With The Guidelines–HF registry to compare HF care, post-discharge outcomes, and total annual Medicare spending by ACO status at discharge.
Methods |
Using adjusted Cox models and accounting for competing risks of death, we compared all-cause mortality and readmission at 1 year by ACO status with reporting of hazard ratios (HR) and 99% confidence intervals (CI).
Results |
The study included 45,259 HF patients from 300 hospitals, with 21.1% assigned to an ACO. Patient characteristics were similar between the two groups with a few exceptions. The ACO patients lived in geographic areas with higher median income ($54400 [IQR $48600-65900] vs $52300 [$45900-61200], P < .0001). Compliance with four HF-specific quality measures was modestly higher in the ACO group (80% vs 76%, P < .0001). In adjusted analysis, ACO status was associated with similar all-cause readmission (HR: 1.03; 99% CI: 0.99, 1.07) but lower risk of 1-year mortality (HR: 0.85; 99% CI: 0.85, 0.90) compared with non-ACO status. Median Medicare spending in the calendar year of hospitalization was similar (ACO $42,737 [IQR $23,011-72,667] vs non-ACO $42,586 [$22,896-72,518], P = 0.06).
Conclusions |
Among Medicare patients hospitalized for HF, participation in an ACO was associated with similar rates of all-cause readmission and no associated cost reductions compared with non-ACO status. There was a lower risk of 1-year mortality associated with ACO participation, which warrants further evaluation.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Khadijah Breathett, MD, MS, served as guest editor for this article. |
|
Disclosures: NL: Consulting AstraZeneca ADD: Research funding from AstraZeneca, Amgen, the American Heart Association, Bayer, Luitpold Pharmaceuticals, the NHLBI, PCORI and Novartis; Consulting with AstraZeneca, LivaNova, Mardil Medical, Novartis and Procyrion. GCF: Consulting Abbott, Amgen, Bayer, Janssen, Medtronic, Novartis AFH: Research funding from American Regent, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck, Novartis, Verily; Consulting with AstraZeneca, Bayer, Boehringer-Ingelheim, Boston Scientific, Merck and Novartis All other authors report no significant disclosures. |
Vol 226
P. 13-23 - Agosto 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?